Performance Shipping WKN: A2QEMK ISIN: MHY673051212 Forum: Aktien Thema: Hauptdiskussion

Gerngeschehen

NOP No Problem

Unter 0,45 kaufen kaufen kaufen,…. Wir die nächsten Jahre niemals darunter gehen,… jeder der unter 0,45 Kauf ist ein Gewinner über die nächsten Jahre,…. 💰💰💰💰🚀🚀🚀💯💯💯🔝🔝🔝🔝

NOP- ?

Aufmerksam lesen Leute,… https://stocktwits.com/TDogxw/message/478289912

Abrakadabra NOP werde meistens sehr unterschätzt,… es gibt auch Fehlgriffe da ich keine Glaskugel habe, aber wer sich auskennt ist finanziell Unabhängig,… und ich gebe gerne weiter,… zudem können WIR es möglich machen,… 💰💰💰💰🚀🚀🚀🚀

Hier wird die Reise hingehen https://stocktwits.com/WolfOfLouisiana/message/478282582

Danke dir Moon77

Hier aber wieder was zum eigentlichen Thema,… was ein Tanker einbringt https://stocktwits.com/Paradox01/message/478284248

https://m-de.marketscreener.com/kurs/aktie/QUOIN-PHARMACEUTICALS-LT-30382148/unternehmen/

https://sec.report/Document/0001104659-22-089784/

Zu Q UO in https://sec.report/Document/0001104659-22-089784/

ASHBURN, Va., Aug. 11, 2022 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the “Company” or “Quoin”), a clinical stage, specialty pharmaceutical company focused on rare and orphan diseases, announced today that its second quarter 2022 financial results will be reported on Thursday, August 18, 2022 before the open of the financial markets. Management will also host a webcast and conference call on August 18, 2022 at 8:30 a.m. ET to discuss the results and provide a corporate update. The live call can also be accessed by dialing 1-877-270-2148 (domestic) or 1-412-902-6510 (international). The live and archived webcast of the call may be accessed on the Quoin Pharmaceuticals website under the Investors section: https://investors.quoinpharma.com/news-and-events/events-and-presentations. About Quoin Pharmaceuticals Ltd. Quoin Pharmaceuticals Ltd. is a clinical stage specialty pharmaceutical company focused on developing and commercializing therapeutic products that treat rare and orphan diseases. We are committed to addressing unmet medical needs for patients, their families, communities and care teams. Quoin’s innovative pipeline comprises four products in development that collectively have the potential to target a broad number of rare and orphan indications, including Netherton Syndrome, Peeling Skin Syndrome, Palmoplantar Keratoderma, Scleroderma, Epidermolysis Bullosa and others. For more information, visit: www.quoinpharma.com or LinkedIn for updates. For further information, contact: Investor Relations PCG Advisory Stephanie Prince sprince@pcgadvisory.com (646) 863-6341

Kann man im MonatsChart sehen!